Edgar Filing: NEOGENOMICS INC - Form 8-K

NEOGENOMICS INC

Form 8-K July 24, 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 24, 2018

NEOGENOMICS, INC.

(Exact name of registrant as specified in its charter)

Nevada 001-35756 74-2897368 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.)

12701 Commonwealth Drive, Suite 9, Fort Myers, Florida 33913 (Address of principal executive offices) (Zip Code)

(239) 768-0600

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written

communications

pursuant to Rule

425 under the

Securities Act (17

CFR 230.425)

Soliciting material

pursuant to Rule

14a-12 under the

Exchange Act (17

CFR 240.14a-12)

Pre-commencement

communications

pursuant to Rule

14d-2(b) under the

Exchange Act (17

CFR 240.14d-2(b))

Pre-commencement

communications

Edgar Filing: NEOGENOMICS INC - Form 8-K

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Edgar Filing: NEOGENOMICS INC - Form 8-K

Item 2.02 Results of Operations and Financial Condition.

On July 24, 2018, NeoGenomics, Inc. (the "Company") issued a press release reporting its results for its second fiscal quarter of 2018. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

- (a) Not applicable
- (b) Not applicable
- (c) Not applicable
- (d) Exhibits.
- 99.1 Press Release of NeoGenomics, Inc. dated July 24, 2018.

Exhibit Index

Exhibit Description No.

Press Release of NeoGenomics, Inc. dated July 24, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOGENOMICS, INC.

By: /s/ Sharon A. Virag Sharon A Virag Chief Financial Officer July 24, 2018